BOTULINUM TOXIN CONTAINING COMPOSITION Russian patent published in 2021 - IPC A61K38/48 A61K47/36 A61Q19/08 A61Q19/00 A61K38/16 A61K31/728 

Abstract RU 2743746 C2

FIELD: pharmaceuticals.

SUBSTANCE: present invention refers to a composition containing (a) botulinum toxin and (b) non-crosslinked hyaluronic acid, and its application for treating or preventing dystonia, spastic condition and/or wrinkles. Besides, the present invention refers to a method for cosmetic smoothing or wrinkle prevention, which involves the stage of introduction of the present composition. Described is a composition for preventing or treating a disease or condition which can be prevented or cured by botulinum neurotoxin A, comprising a) 2–4 or 20–40 units of botulinum neurotoxin A per milligram of non-crosslinked hyaluronic acid, b) 2.5–9 mg of non-crosslinked hyaluronic acid having average molecular weight from 2.5 to 4.5 MDA, where the disease or condition is selected from focal, segmental or generalized dystonia, spastic condition or wrinkles, and where the polydispersity index of the non-crosslinked hyaluronic acid ranges from 1.1 to 4.0.

EFFECT: technical result is creation of improved composition with botulinum neurotoxin, providing prolonged action of botulinum toxin, prevention or at least considerable reduction of undesirable by-effects.

12 cl, 1 ex, 2 dwg

Similar patents RU2743746C2

Title Year Author Number
LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE 2017
  • Yarstad, Anders
  • Friis, Anna
  • Shtal, Ulf
  • Gurell, Ann
  • Agren, Barbro
  • Edstrom, Emiliya
  • Pikett, Endryu
RU2741497C2
CLOSTRIDIAL NEUROTOXINS WITH MODIFIED PERSISTENCE 2009
  • Frevert Jurgen
RU2524429C2
PHARMACEUTICAL COMPOSITION FOR TREATING PAIN SYNDROME IN FOOT, COMPRISING BOTULINUM TOXIN AND HYALURONIC ACID, AND METHOD OF TREATING PAIN SYNDROME IN FOOT WITH USE THEREOF 2018
  • Jang, Sung Su
  • Lee, Haksup
  • Ahn, Yongshik
  • Kim, Jonghyo
  • Shin, Seungjin
RU2734159C1
PROLONGED-RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING POLOXAMER 2009
  • Khant Terrens Dzh.
RU2482874C2
HIGH INTRODUCTION RATE OF NEUROTOXIC COMPONENT OF BOTULINUM TOXIN 2007
  • Marks Mattias
  • Grafe Zuzanne
  • Benekke Rajner
  • Dressler Dirk
RU2453333C2
LIQUID PHARMACEUTICAL COMPOSITION OF BOTULINUM TOXIN 2008
  • Dzjung Khun Kho
  • Jang Gi Khueok
  • Kim Khak Voo
  • Voo Khee Dong
  • Rkhee Chang Khoon
RU2440825C2
SIMULTANEOUS, SEPARATE OR SEPARATED IN TIME THERAPEUTIC APPLICATION OF, AT LEAST, ONE BOTULIC NEUROTOXIN AND, AT LEAST, ONE OPIATE DERIVATIVE 2007
  • Oge Mishel'
  • Favr Kristin
  • Shabrie De Lasson'Er P'Er-Eht'Enn
RU2434637C2
METHOD FOR BOTULINUM TOXIN PRODUCTION 2014
  • Kim Chon Sej
  • Son Kvan En
  • Min Ken Min
  • An En Tuk
RU2627159C2
PEG-YLATED MUTANT TOXIN CLOSTRIDIUM BOTULINUM 2007
  • Frefert Jurgen
  • Shpekht Fol'Ker
RU2426739C2
COMPOSITIONS AND METHODS FOR IMPROVING DRUG THERAPY WITH METAL ION DEPENDANT AGENTS 2010
  • Soparkar Charles N. S.
RU2540520C2

RU 2 743 746 C2

Authors

Fink, Klaus

Tejlor, Garold

Russ, German

Boderke, Peter

Dates

2021-02-25Published

2017-02-28Filed